[{"id":"4b52c1e0-7f02-447c-817c-f6773b95d1e0","acronym":"TRUST-II","url":"https://clinicaltrials.gov/study/NCT04919811","created_at":"2021-06-10T01:52:36.470Z","updated_at":"2024-07-02T16:35:19.277Z","phase":"Phase 2","brief_title":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","source_id_and_acronym":"NCT04919811 - TRUST-II","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 fusion","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibtrozi (taletrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 224","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-15"},{"id":"eb70c6e6-301a-44ee-9150-3a7d0e444854","acronym":"TRUST","url":"https://clinicaltrials.gov/study/NCT04395677","created_at":"2021-01-17T17:16:15.961Z","updated_at":"2024-07-02T16:35:31.201Z","phase":"Phase 2","brief_title":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","source_id_and_acronym":"NCT04395677 - TRUST","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 fusion","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibtrozi (taletrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 07/07/2020","start_date":" 07/07/2020","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-10-30"},{"id":"455bb5f8-dfe6-4827-a577-3f71d18ec8ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT04617054","created_at":"2021-01-19T20:33:44.655Z","updated_at":"2024-07-02T16:36:28.868Z","phase":"Phase 2","brief_title":"Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene","source_id_and_acronym":"NCT04617054","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibtrozi (taletrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2021-06-21"},{"id":"8f3fcd9d-3554-40b3-abe4-2fc941420095","acronym":"","url":"https://clinicaltrials.gov/study/NCT02279433","created_at":"2021-01-18T10:44:10.387Z","updated_at":"2024-07-02T16:36:40.799Z","phase":"Phase 1","brief_title":"A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b","source_id_and_acronym":"NCT02279433","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" KRAS • ROS1 • NTRK1 • NTRK3 • NTRK2 • RAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS • ROS1 • NTRK1 • NTRK3 • NTRK2 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibtrozi (taletrectinib)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-09-22"}]